OncoSil Medical has announced the successful completion of patient recruitment for the PANCOSIL study.
The PANCOSIL study is an open-label, single-arm phase 1–2 feasibility trial initiated by Amsterdam University Medical Center (Amsterdam UMC) in The Netherlands. The study is evaluating the safety and feasibility of computed tomography (CT)-guided percutaneous radionuclide therapy using the OncoSil device in patients with non-progressive locally advanced pancreatic cancer (LAPC).
OncoSil Medical announced ethics committee approval for the PANCOSIL study on 5 June 2023 and first patient treatment on 29 November 2023. A total of 20 patients have now been enrolled in the study. Its primary objective is to assess a novel delivery method for the OncoSil device via a CT-guided percutaneous approach. The company have stated in a recent press release that this approach has the potential to simplify administration and lower barriers to adoption, supporting wider market penetration and real-world clinical use.
This innovative method represents a potentially transformative step in how OncoSil therapy can be delivered—providing a less invasive and more accessible option for treatment centres worldwide. OncoSil Medical anticipates preliminary data from the PANCOSIL study to be available in late calendar 2025.
Marc Besselink, lead investigator at Amsterdam UMC, said: “By achieving full recruitment, the PANCOSIL study opens a new chapter in the evolution of localised treatment of pancreatic cancer. By developing CT-guided percutaneous administration under local anaesthesia, we will make OncoSil therapy more broadly applicable. The study has the potential to redefine the delivery model and bring meaningful benefits to both clinicians and patients.”
Nigel Lange, chief executive officer and managing director of OncoSil Medical, said: “The completion of recruitment in the PANCOSIL study represents a critical milestone in the clinical development of the OncoSil device. On behalf of OncoSil Medical, I want to thank Besselink and the entire Amsterdam UMC team for their leadership and vision over the design and implementation stages of the PANCOSIL study.
The study’s importance to our device’s development process cannot be overestimated, with it representing a major opportunity to unlock new pathways for delivering our therapy and accelerating its adoption in clinical practice. We now look forward to the results from the PANCOSIL study and expect that they will make an invaluable contribution to our efforts to make the OncoSil device a go-to treatment for patients with unresectable locally advanced pancreatic cancer, one that has acknowledged flexibility and is widely accessible.”
